Zoetis Inc.

NYSE:ZTS Voorraadrapport

Marktkapitalisatie: US$79.8b

Zoetis Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Zoetis is de winst gegroeid met een gemiddeld jaarlijks percentage van 9.8%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 2.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 7.8% per jaar. Het rendement op eigen vermogen van Zoetis is 46.6%, en het heeft een nettomarge van 26.6%.

Belangrijke informatie

9.8%

Groei van de winst

10.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei7.8%
Rendement op eigen vermogen46.6%
Nettomarge26.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Oct 26
Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Zoetis: A Solid Choice For The Young Dividend Growth Investor

Oct 09

Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Oct 08
Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Zoetis: Investing In Pet Health And Portfolio Wealth

Sep 26

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

Sep 20
Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Aug 30
There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

Aug 13

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Aug 07

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Jul 16
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

Jul 03

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

Jun 11

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Jun 10
A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

May 23
Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

May 22

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04
The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12
Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03
Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01
Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14
Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18
Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04
Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12
Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10
Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16
These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Opbrengsten en kosten

Hoe Zoetis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSE:ZTS Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 249,1522,4302,258674
30 Jun 248,9152,3442,218659
31 Mar 248,7342,3912,193634
31 Dec 238,5442,3442,151614
30 Sep 238,3712,2802,100588
30 Jun 238,2222,2132,076570
31 Mar 238,0942,0712,049559
31 Dec 228,0802,1142,009539
30 Sep 228,0072,0672,088529
30 Jun 227,9952,0902,091527
31 Mar 227,8912,0732,057512
31 Dec 217,7762,0372,001508
30 Sep 217,6161,9821,926503
30 Jun 217,4121,9091,841483
31 Mar 217,0121,7741,734474
31 Dec 206,6751,6381,713463
30 Sep 206,5421,6631,665462
30 Jun 206,3401,6171,637462
31 Mar 206,3391,6111,655462
31 Dec 196,2601,5001,636457
30 Sep 196,1501,4611,553450
30 Jun 196,0461,3751,529446
31 Mar 195,9141,3881,482437
31 Dec 185,8251,4281,482432
30 Sep 185,7211,1641,424417
30 Jun 185,5881,1151,386405
31 Mar 185,4429781,362389
31 Dec 175,3078641,325382
01 Oct 175,1249371,320380
02 Jul 175,0188781,325374
02 Apr 174,9578551,323376
31 Dec 164,8888211,316376
02 Oct 164,8856891,362375
03 Jul 164,8586391,374376
03 Apr 164,8253781,383372
31 Dec 154,7653391,402362
27 Sep 154,8114431,464378
28 Jun 154,8074201,483380
29 Mar 154,7905931,506388
31 Dec 144,7855831,512396
28 Sep 144,7195621,461391
29 Jun 144,6125271,455390
30 Mar 144,5685191,429389
31 Dec 134,5615041,428392

Kwaliteitswinsten: ZTS heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (26.6%) ZTS } zijn lager dan vorig jaar (27.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van ZTS is de afgelopen 5 jaar met 9.8% per jaar gegroeid.

Versnelling van de groei: De winstgroei van ZTS over het afgelopen jaar ( 6.6% ) ligt onder het 5-jarig gemiddelde ( 9.8% per jaar).

Winst versus industrie: De winstgroei ZTS over het afgelopen jaar ( 6.6% ) overtrof de Pharmaceuticals -sector 54.6%.

Rendement op eigen vermogen

Hoge ROE: Hoewel het rendement op eigen vermogen ( 46.58% ) van ZTS uitstekend is, is deze metriek vertekend vanwege hun hoge schuldenniveau.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y